Clinical trials: Anemia of End Stage Renal Disease
Anemia, Renal Failure
Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.
- Trial name
- NCT00318812
- Testing
- Heme Iron Polypeptide (Proferrin), Iron sucrose (Venofer)
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Kidney Disease, Renal Anemia
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells.
- Trial name
- NCT05970172
- Testing
- Roxadustat
- Where
- 47 sites in Belgium, Croatia and 17 more
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Failure, Chronic, Hemodialysis
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
- Trial name
- NCT05211167
- Testing
- Human Erythropoiesis Injection (CHO cell), Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Pure Red-cell Aplasia
A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (EPO) antibody positive pure red cell aplasia (PRCA) in participants with…
- Trial name
- NCT00211068
- Testing
- No intervention
- Where
- 22 sites in Brazil, France and 5 more
- Volunteers
- 124 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Kidney Failure, Chronic
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.
- Trial name
- NCT01999582
- Testing
- Sotatercept
- Where
- 23 sites in Belgium, Germany and 3 more
- Volunteers
- 50 people
- Sponsor
- Celgene
Anemia, End Stage Renal Disease
Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant
In this End Stage Renal Disease (ESRD) patients who need Erythropoietin (epo) hormone will get it by a small implant of skin using their own skin, the implant will be treated in the laboratory and programmed to secrete Epo.
- Trial name
- NCT01555515
- Testing
- implantation of autologous skin graft after ex-vivo treatment, Subcutan implantation of autologus skin graft after ex-vivo treatment
- Volunteers
- 4 people
- Sponsor
- Medgenics Medical Israel Ltd.
Anemia, Kidney Failure
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
Renal anemia is common in people receiving long-term hemodialysis and is usually treated with erythropoiesis-stimulating agents (ESAs).
- Conditions
- Anemia, Kidney Failure, End-Stage Renal Disease, Renal Dialysis
- Trial name
- L-CAR-ESA (NCT07160452)
- Testing
- Levocarnitine Injection, Usual ESA-Based Anemia Care
- Volunteers
- 94 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Anemia in End Stage Renal Disease
Study of Rule-Based Algorithms in Anemia Management in Prevalent Hemodialysis Patients and Its Relation to Patients' Outcomes
The study will assess role of rule based algorithm in anemia management in hemodialysis patients and its relation to patient's mortality
- Trial name
- NCT06996717
- Testing
- ESA
- Where
- Egypt
- Volunteers
- 145 people
- Sponsor
- Ain Shams University
CKD Anemia in Dialysis Participants
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.
- Trial name
- NCT04059913
- Testing
- Roxadustat
- Where
- 25 sites in China
- Volunteers
- 318 people
- Sponsor
- Kyntra Bio
Chronic Renal Failure, Chronic Kidney Disease
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT00453973
- Testing
- peginesatide
- Where
- 20 sites in Bulgaria, Poland and 2 more
- Volunteers
- 114 people
- Sponsor
- Affymax
Anemia in End-Stage Renal Disease
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
This Phase III, randomized, two-armed, parallel, double-blind, active-controlled clinical trial is designed to compare efficacy and safety of CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of…
- Trial name
- NCT03408639
- Testing
- CinnaPoietin®, Eprex®, Nephrovit
- Where
- 8 sites in Iran
- Volunteers
- 156 people
- Sponsor
- Cinnagen
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Anemia of Chronic Kidney Disease
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
This study is to evaluate 24-week efficacy and 52 week immunogenicity of subcutaneous Eporon versus Epoetin Alfa (Eprex) in the treatment of anemia associated with chronic renal failure in pre-dialysis patients.
- Trial name
- NCT03521713
- Testing
- EPORON, EPREX
- Where
- Turkey (Türkiye)
- Volunteers
- 214 people
- Sponsor
- Dong-A ST Co., Ltd.
Gut Micrbota and Its Relation to Anemia of CKD Patients
Relationship Between Gut Microbiota And Anemia In Patients With Chronic Renal Failure
The human intestinal tract harbours a diverse and complex microbial community which plays a central role in human health. It has been estimated that our gut contains in the range of 1000 bacterial species and 100-fold more genes…
- Trial name
- NCT03220685
- Testing
- Stool analysis
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Healthy Volunteers
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.
- Trial name
- NCT02327546
- Testing
- AKB-6548, Ferrous Sulfate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 1 (NCT00598273)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 490 people
- Sponsor
- Affymax
Anemia of Chronic Kidney Disease, Chronic Renal Failure
Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients
This observational study aims to compare long-acting darbepoetin alpha versus short-acting epoetin alpha erythropoietin-stimulating agents in Egyptian hemodialysis patients.
- Conditions
- Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia
- Trial name
- NCT05699109
- Where
- Egypt
- Volunteers
- 127 people
- Sponsor
- Helwan University
Anemia in Chronic Kidney Disease Patients Not on Dialysis
ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-
This study is to evaluate the safety and the dose-response of ASP1517 in the treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied intermittently.
- Trial name
- NCT01964196
- Testing
- ASP1517
- Where
- 7 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Astellas Pharma Inc
Pure Red-Cell Aplasia, Chronic Kidney Failure
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate…
- Trial name
- PRIMS (NCT00391287)
- Where
- 387 sites in Australia, Belgium and 13 more
- Volunteers
- 15,334 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Kidney Failure, Chronic, Anemia
A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients
The purpose of this study in early hemodialysis patients (on dialysis 3 to 18 months) is to assess the effect of correction versus partial correction of anemia using epoetin alfa on heart pumping function.
- Trial name
- NCT00261521
- Testing
- epoetin alfa
- Volunteers
- 596 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.